-
公开(公告)号：US20140302041A1
公开(公告)日：2014-10-09
申请号：US14127415
申请日：2012-06-22
Applicant: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
Inventor： Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
IPC: C07K16/30 , G01N33/574 , C07K16/40
CPC classification number: C07K16/30 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K16/40 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57492
Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9，SEQ ID NO：10和SEQ ID NO：11结合Ax1的细胞外结构域。
-
公开(公告)号：US20140227283A1
公开(公告)日：2014-08-14
申请号：US14127416
申请日：2012-06-22
Applicant: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
Inventor： Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
IPC: C07K16/28 , G01N33/68 , G01N33/574
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/32 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6872
Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9和SEQ ID NO：10与Ax1的细胞外结构域结合。
-
公开(公告)号：US20140141019A1
公开(公告)日：2014-05-22
申请号：US14116562
申请日：2012-05-11
Applicant: Abdelhakim Kharrat , Olivier Dubreuil , Yassamine Lazrek , Philippe Mondon , Khalil Bouayadi , Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege A. Gaborit
Inventor： Abdelhakim Kharrat , Olivier Dubreuil , Yassamine Lazrek , Philippe Mondon , Khalil Bouayadi , Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege A. Gaborit
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/32 , C07K2317/21 , C07K2317/34 , C07K2317/76
Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
Abstract translation: 本发明涉及针对HER3的抗体及其在治疗癌症中的用途。
-
公开(公告)号：US09409988B2
公开(公告)日：2016-08-09
申请号：US14127416
申请日：2012-06-22
Applicant: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
Inventor： Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/32 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6872
Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9和SEQ ID NO：10与Ax1的细胞外结构域结合。
-
Patent Agency Ranking
公开(公告)号：US09346883B2
公开(公告)日：2016-05-24
申请号：US14116562
申请日：2012-05-11
Applicant: Abdelhakim Kharrat , Olivier Dubreuil , Yassamine Lazrek , Philippe Mondon , Khalil Bouayadi , Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege A. Gaborit
Inventor： Abdelhakim Kharrat , Olivier Dubreuil , Yassamine Lazrek , Philippe Mondon , Khalil Bouayadi , Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege A. Gaborit
CPC classification number: C07K16/2863 , C07K16/32 , C07K2317/21 , C07K2317/34 , C07K2317/76
Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
Abstract translation: 本发明涉及针对HER3的抗体及其在治疗癌症中的用途。
-
公开(公告)号：US20090214541A1
公开(公告)日：2009-08-27
申请号：US12086725
申请日：2006-12-15
Applicant: Stephen D. Gillies , David Azria , Christel Larbouret , Andre Pelegrin
Inventor： Stephen D. Gillies , David Azria , Christel Larbouret , Andre Pelegrin
IPC: A61K39/395 , A61P35/00
CPC classification number: C07K16/2863 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/32 , C07K2317/24 , C07K2317/31
Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
Abstract translation: 本发明涉及用于治疗癌症的抗EGFR抗体和抗Her2抗体的组合使用，特别适用于表达高水平的EGFR型和低水平的HER2的癌症。 本发明特别涉及针对HER2受体的单克隆抗体“曲妥珠单抗”（HERCEPTIN），当与针对EGF受体的单克隆抗体“matuzumab”（hmAB 425，EMD 72000）组合时，其效力可以显着增加 。 联合治疗适用于患有具有所述受体分布的癌症的患者，优选胰腺癌。
-
公开(公告)号：US09249228B2
公开(公告)日：2016-02-02
申请号：US14127415
申请日：2012-06-22
Applicant: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
Inventor： Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
IPC: C07K16/28 , C07K16/30 , A61K39/395 , C07K16/40 , G01N33/574 , A61K39/00
CPC classification number: C07K16/30 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K16/40 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57492
Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9，SEQ ID NO：10和SEQ ID NO：11结合Ax1的细胞外结构域。
-
公开(公告)号：US09127065B2
公开(公告)日：2015-09-08
申请号：US14118747
申请日：2012-05-21
Applicant: Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege Gaborit , Yassamine Lazrek
Inventor： Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege Gaborit , Yassamine Lazrek
IPC: A61K39/395 , C07K16/28 , C07K16/32
CPC classification number: C07K16/2863 , C07K16/32 , C07K2317/34 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
Abstract translation: 本发明提供分离的抗人HER3抗体或其片段。 更具体地说，本发明提供了一种分离的单克隆抗体，其特异性结合HER-3的细胞外结构域，并且与从作为CNCM-I-4486保藏的杂交瘤得到的抗体竞争结合人HER-3的细胞外结构域。 本发明中描述的抗体可用于治疗癌症。
-
公开(公告)号：US20140112931A1
公开(公告)日：2014-04-24
申请号：US14118747
申请日：2012-05-21
Applicant: Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege Gaborit , Yassamine Lazrek
Inventor： Thierry Chardes , Andre Pelegrin , Christel Larbouret , Nadege Gaborit , Yassamine Lazrek
IPC: C07K16/28
CPC classification number: C07K16/2863 , C07K16/32 , C07K2317/34 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
Abstract translation: 本发明提供分离的抗人HER3抗体或其片段。 更具体地说，本发明提供了一种分离的单克隆抗体，其特异性结合HER-3的细胞外结构域，并且与从作为CNCM-I-4486保藏的杂交瘤得到的抗体竞争结合人HER-3的细胞外结构域。 本发明中描述的抗体可用于治疗癌症。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
